Unesbulin is under clinical development by PTC Therapeutics and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase I drugs for High-Grade Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Unesbulin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Unesbulin (PTC-596) is under development for the treatment of glioblastoma multiforme, anaplastic astrocytoma, acute myeloblastic leukemia, acute lymphocytic leukemia, fibrosarcoma, leiomyosarcoma, pediatric diffuse intrinsic pontine glioma and advanced solid tumors such as epithelial ovarian, primary peritoneal or fallopian tube carcinoma, endometrioid adenocarcinoma.The drug candidate is administered orally. It is a small-molecule inhibitor of BMI1. It is developed based on GEMS technology.
PTC Therapeutics overview
PTC Therapeutics discovers, develops, and markets medicines for the treatment of rare disorders. Its marketed products include Evrysdi (risdiplam) for spinal muscular atrophy, Translarna (ataluren) and Emflaza (deflazacort) for the treatment of Duchenne muscular dystrophy. The company’s pipeline candidates target the treatment of Huntington’s disease; children with inherited mitochondrial disease; leiomyosarcoma; acute myelogenous leukemia; and aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics works in collaboration with various biotechnology and pharmaceutical companies for advancing its pipeline candidates. It operates through its subsidiaries in the US and Europe. PTC Therapeutics is headquartered in South Plainfield, New Jersey, the US.
For a complete picture of Unesbulin’s drug-specific PTSR and LoA scores, buy the report here.